HeyJaredMelanoma Matters
From the UK to the USA - Melanoma Matters is on a mission!Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time.
- Indexed episodes, last 90 days
- 6
- Latest publication
- Sep 1, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 24, 2026
Latest episodes
Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098) (opens the original)
Read excerpt
Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short Hobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward. James Larkin and Sapna Patel also dig into a bigger question: if combination therapy helps in metastatic di
Ep 86: Teaser Tudriqev (RP1) FDA Approval (opens the original)
Read excerpt
James asks the big question
Ep 87: INTerpath-001 Press Release - August 2026 (opens the original)
Read excerpt
In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful" results. As James puts it, one of these is binary, the other is subjective.
Ep 86: Tudriqev (RP1) FDA Approval (opens the original)
Read excerpt
In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data. It's a long episode with a short fact c
Ep 85: Surgical considerations for TIL (opens the original)
Read excerpt
In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of interest include optimal anatomic site(s), size (is bigger always better?), number of lesions and which of these components comprise a successful ex vivo expansion of TIL
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.